Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 1099 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
ORIGINAL ARTICLE
Year : 2020  |  Volume : 24  |  Issue : 5  |  Page : 402-405

Health-related quality of life in acromegaly patients: Results from generic and disease-specific questionnaires


1 Programa de Pos-Graduacao em Patologia, Universidade Federal de Ciencias da Saude de Porto Alegre (UFCSPA), Porto Alegre, RS, Brasil
2 Centro de Neuroendocrinologia, Complexo Hospitalar Santa Casa, UFCSPA, Porto Alegre, RS, Brasil
3 Programa de Pos-Graduacao em Patologia, Universidade Federal de Ciencias da Saude de Porto Alegre (UFCSPA); Centro de Neuroendocrinologia, Complexo Hospitalar Santa Casa, UFCSPA, Porto Alegre, RS, Brasil

Correspondence Address:
Miriam da C. Oliveira
Rua Sarmento Leite, 245; Sala 402, Predio 1/90050-170 - Porto Alegre, RS
Brasil
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijem.IJEM_401_20

Rights and Permissions

Introduction: Acromegaly is associated with high morbidity, but still controversial impact on the overall quality of life (QoL). Material and Methods: We evaluated QoL using a generic (SF-36) and a disease-specific questionnaire (AcroQoL) in an acromegalic cohort. Results: Sixty-nine patients answered the questionnaires and had their records reviewed. In the SF-36 questionnaire, except for the Social Aspects domain, all others revealed a reduction in scores from 9.7 to 38.9%, when compared to the non-acromegalics. The cure was positively correlated with mental health (P = 0.023) and drug control was correlated with mental health (P = 0.023) and functional capacity (P = 0.013). In the AcroQoL questionnaire, the mean scores ranged from 54.7% to 72.8%. The use of antidepressants correlated with lower scores on the total AcroQoL (P = 0.039) and physical complaints (P = 0.003). The growth hormone value at diagnosis showed an inverse correlation with the total AcroQoL score (P = 0.014), Appearance Issues subscale (P = 0.081), and Personal Relations (P = 0.002). IGF-1 values at diagnosis and at the last visit showed no statistical correlation with any of the questionnaires. Conclusion: The finding of a reduction in QoL scores with both SF-36 and AcroQoL allows us to suggest this evaluation as part of the initial assessment and follow-up in acromegaly, to act globally on the individual's health condition.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed363    
    Printed4    
    Emailed0    
    PDF Downloaded62    
    Comments [Add]    

Recommend this journal